You are here

Eliav Barr, MD

Life Sciences Council Member
Head, Global Clinical Development, and Chief Medical Officer, Merck

Dr. Eliav Barr became head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), in April 2022. Previously he was Senior Vice President, Global Clinical Development and he has held positions of increasing responsibility including leadership roles in oncology and infectious diseases clinical development. Barr oversaw the company’s Vaccines/Infectious Disease area during a period of high productivity, including the development of novel therapies for chronic hepatitis C and HIV-1 infections. Most recently he led MRL’s Global Medical Affairs organization from 2018 to January 2022, significantly expanding Merck’s scientific engagement and implementation efforts in oncology, vaccines and more. In his latest role Barr leads all late-stage clinical development for Merck’s expansive human health portfolio and pipeline.

Barr led the development of Merck’s human papillomavirus (HPV) vaccines, which have become key tools in the global effort to reduce the burden of certain cancers and diseases caused by HPV.

Barr is a cardiologist by training. He received his undergraduate degree from Penn State University and his medical degree from Sidney Kimmel Medical College, Thomas Jefferson University. He completed his Internal Medicine residency and Cardiology Fellowship at Johns Hopkins University, and subsequently pursued post-doctoral training at the University of Michigan. Prior to joining Merck in 1995, he held a faculty position at the University of Chicago. In 2019, he received a Penn State Alumni Fellow Award for his dedication to the development of medicines and vaccines that treat and prevent infectious diseases.